Interleukin Patents (Class 424/85.2)
-
Patent number: 10987403Abstract: Disclosed herein are compositions including cyclodextrin and Nle3-A(1-7) [Asp-Arg-Me-Tyr-Ile-His-Pro (SEQ ID NO: 1)] and their use in treating various disorders.Type: GrantFiled: March 9, 2018Date of Patent: April 27, 2021Assignee: University of Southern CaliforniaInventors: Kevin J. Gaffney, Stan G. Louie, Kathleen E. Rodgers
-
Patent number: 10987371Abstract: A method of reducing the risk of filovirus hemorrhagic fever or a symptom thereof in a mammal host exposed to a filovirus (e.g., Ebola or Zika virus), comprising administering an effective amount of quercetin-3 ?-O-D-glucoside (Q3G) or an analogue thereof, or a composition comprising Q3G or analogue thereof and a pharmaceutically acceptable carrier, to said host prior to said exposure.Type: GrantFiled: June 7, 2018Date of Patent: April 27, 2021Inventors: Michel Chrétien, Majambu Mbikay, Xiangguo Qiu
-
Patent number: 10981903Abstract: The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L1, L2, RA, RC, RD, RE, m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases.Type: GrantFiled: November 28, 2018Date of Patent: April 20, 2021Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, Tinghu Zhang
-
Patent number: 10967070Abstract: Provided herein are cell penetrating conjugates. The conjugates include a non-cell penetrating protein attached to a phosphorothioate nucleic acid or phosphorothioate polymer backbone, wherein the phosphorothioate nucleic acid or phosphorothioate polymer backbone enhances intracellular delivery of the non-cell penetrating protein. Also provided are compositions and kits comprising the cojugates.Type: GrantFiled: February 29, 2016Date of Patent: April 6, 2021Assignee: CITY OF HOPEInventors: Andreas Herrmann, Hua Yu, Piotr Marek Swiderski, John Ernest Shively, Lin Li
-
Patent number: 10966927Abstract: The present disclosure is broadly concerned with petrolatum-based compositions as a suspension matrix for the active ingredients. The disclosure is also concerned with processes for forming stable emulsions of active ingredients in petrolatum.Type: GrantFiled: June 30, 2020Date of Patent: April 6, 2021Assignee: GLOBAL HEALTH SOLUTIONS LLCInventor: Bradley Burnam
-
Patent number: 10967060Abstract: The present disclosure provides combinations of immunologic inhibitors for the treatment of cancer. In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7.Type: GrantFiled: July 10, 2018Date of Patent: April 6, 2021Assignee: The University of ChicagoInventors: Thomas F. Gajewski, Stefani Spranger, Michael Leung
-
Patent number: 10954492Abstract: Described are improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the described improved processes relate to improved processes for producing viral DNA template. Also described are improved processes for chromatography purification of nucleic acid-containing compositions, in which the nucleic acid is quantified in chromatography fractions using a rapid detection method of the one or more nucleic acid sequences of the nucleic acid-containing composition, such as detection by real time RT-qPCR. In addition, improved processes for production and purification of oncolytic poliovirus, such as PVS-RIPO, are described. Compositions generated using these methods are also provided.Type: GrantFiled: June 10, 2016Date of Patent: March 23, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Trevor Lane Broadt, Samir Hussein Shaban, Yueqing Xie, Jianwei Sean Zhu, George Mitra
-
Patent number: 10946022Abstract: Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.Type: GrantFiled: July 30, 2019Date of Patent: March 16, 2021Assignee: ONCOCEUTICS, INC.Inventors: Joshua E. Allen, Martin Stogniew, Varun Vijay Prabhu
-
Patent number: 10940200Abstract: The present invention provides methods of modulating an immunological disorder or an immune response. The methods include administering to a subject or a cell an effective amount of an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier. Compositions including an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier are also provided.Type: GrantFiled: September 28, 2016Date of Patent: March 9, 2021Assignee: East Carolina UniversityInventor: Mark D. Mannie
-
Patent number: 10912798Abstract: A method is provided, inter alia, for treating a subject suffering from an infectious or neoplastic disease with immunotherapy. The method includes determining the critical concentration of immune cells required to treat or eradicate an infectious or neoplastic disease in the subject using an in vitro assay of the present invention; and administering to the subject the critical concentration of immune cells determined in the assay.Type: GrantFiled: October 9, 2018Date of Patent: February 9, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventors: Samuel C. Silverstein, John D. Loike, Sadna Budhu, Peter Lee
-
Patent number: 10906952Abstract: The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.Type: GrantFiled: March 7, 2016Date of Patent: February 2, 2021Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, EBERHARD KARLS UNIVERSITÄT TÜBINGENInventors: Jung Gundram, Helmut Salih, Cornelia Lindner, Berit Lochmann
-
Patent number: 10888621Abstract: Provided are an injectable tissue adhesive hydrogel including gamma-cyclodextrin (?-CD). When such an injectable tissue adhesive hydrogel including the ?-CD is used as a skin glue, based on a fact that the ?-CD has a bigger hydrophobic cavity than that of ?- and ?-CDs, the injectable tissue adhesive hydrogel including the ?-CD has stronger interactions than host-guest interactions. In addition, hydrogen bonding in the injectable tissue adhesive hydrogel including the ?-CD can improve both cohesiveness and adhesiveness of gelatin. The injectable tissue adhesive hydrogel including the ?-CD having excellent cell viability is used for adhesion of a skin incision, to thereby effectively promote tissue regeneration.Type: GrantFiled: March 31, 2017Date of Patent: January 12, 2021Assignees: AJOU UNIVERSITY INDUSTRY—ACADEMIC COOPERATION FOUNDATION, INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Ki Dong Park, Kyung Min Park, Yun Ki Lee, Thi Thai Thanh Hoang, Thi Phuong Le
-
Patent number: 10889653Abstract: The present invention is directed to novel heterodimeric antibodies.Type: GrantFiled: November 25, 2015Date of Patent: January 12, 2021Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
-
Patent number: 10865230Abstract: The invention features soluble fusion protein complexes comprising at least two soluble fusion proteins. For example, the first fusion protein is an anti-CD3 antibody covalently linked to an interleukin-15 (IL-15) polypeptide or functional fragment thereof. The second fusion protein comprises a binding domain that recognizes disease antigens, wherein this domain is covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. One or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof, and the IL-15 domain of first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.Type: GrantFiled: May 26, 2017Date of Patent: December 15, 2020Assignee: ALTOR BIOSCIENCE, LLCInventors: Bai Liu, Peter Rhode, Hing C. Wong
-
Patent number: 10865226Abstract: Peptides exhibiting melanogenesis promoting activity are described. The peptides increase the activity and expression of tyrosinase and the expression of factors involved in melanogenesis, thereby exhibiting an outstanding effect on melanogenesis. The peptides can be used for the prevention, alleviation, and treatment of hypomelanosis. The outstanding activity and stability stated above allow the peptides to be very favorably applied to medicines, quasi-medicines, and cosmetics.Type: GrantFiled: February 21, 2018Date of Patent: December 15, 2020Assignee: CAREGEN CO., LTD.Inventors: Yong Ji Chung, Eun Mi Kim, Eung-Ji Lee
-
Patent number: 10849963Abstract: The present invention relates to a medicament for use in a method of inducing a cellular cytotoxic immune response, the method comprising the steps of: i) administering to a patient a delivery system comprising (a) a molecule binding to a receptor on the surface of a dendritic cell, (b) an antigen-comprising protein bound to molecule of (a) and (c) a first adjuvant, wherein upon binding of the molecule of (a) to the receptor, the protein of (b) is internalized and processed in the dendritic cell and the antigen comprised in the protein is presented on the surface of the dendritic cell, thereby activating a T cell in the patient; and ii) administering to the patient a re-activator selected from the group consisting of (d) complexed interleukin 2 (IL-2cx), (e) a peptide-loaded major histocompatibility complex class I (MHC-I) presenting cell and a second adjuvant, and (f) a combination of (d) and (e), wherein the peptide is derived from the antigen-comprising protein as defined in step i), thereby reactivating tType: GrantFiled: March 17, 2015Date of Patent: December 1, 2020Assignee: Bundesrepublik Deutschland letztvertreten durch das Robl Koch-Institut vertreten durch seinen PräsidentenInventor: Richard Kroczek
-
Patent number: 10836995Abstract: The present invention is related to a medium additive composition comprising peroxidasin for serum-free cell culture, and a method of performing serum-free culture of cells by using the same.Type: GrantFiled: January 12, 2017Date of Patent: November 17, 2020Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Young Ae Joe, Hyun-Kyung Kim
-
Patent number: 10829535Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.Type: GrantFiled: February 21, 2018Date of Patent: November 10, 2020Assignee: Amgen Inc.Inventors: Marc A. Gavin, Gunasekaran Kannan, Li Li, Joshua T. Pearson, Margaret Karow
-
Patent number: 10818377Abstract: Described herein are polypeptides capable of self-assembling to form homo-oligomers, and methods for designing such polypeptides.Type: GrantFiled: November 15, 2017Date of Patent: October 27, 2020Assignee: University of WashingtonInventors: David Baker, Jorge Fallas, George Ueda, William H. Sheffler, Vanessa Nguyen
-
Patent number: 10808016Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.Type: GrantFiled: August 5, 2019Date of Patent: October 20, 2020Assignee: IMCYSE SAInventors: Luc Vander Elst, Vincent Carlier, Jean-Marie Saint-Remy
-
Patent number: 10799473Abstract: Accelerated senescence has been shown to occur as a primary response to cellular stresses including DNA damaging agents (e.g., ionizing radiation) and is widely believed to be caused by continuous proliferative signaling in the presence of cell cycle arrest. The present disclosure provides a method of reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation. The method comprises administering to a subject before, after, or concurrently with exposure to ionizing radiation an effective amount of a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade.Type: GrantFiled: March 3, 2014Date of Patent: October 13, 2020Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Regina M Day, Ronald-Allan M Panganiban
-
Patent number: 10793875Abstract: Cancer immunotherapy is enhanced by co-expression of cancer associated or tumor-specific (neo)epitopes with co-stimulatory molecules and/or other immune activators. Where desired, treatment may be enhanced by administration of a immune checkpoint inhibitor.Type: GrantFiled: December 7, 2016Date of Patent: October 6, 2020Assignee: Nant Holdings IP, LLCInventors: Patrick Soon-Shiong, Shahrooz Rabizadeh, Kayvan Niazi
-
Patent number: 10793632Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.Type: GrantFiled: August 30, 2017Date of Patent: October 6, 2020Assignee: Xencor, Inc.Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
-
Patent number: 10786551Abstract: The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided.Type: GrantFiled: September 1, 2017Date of Patent: September 29, 2020Assignee: Generon (Shanghai) Corporation Ltd.Inventors: Yu Liang Huang, Zhi Hua Huang, Qi Sun
-
Patent number: 10781242Abstract: The present invention relates to interleukin-2 fusion proteins. More specifically, the invention provides, in part, fusion proteins that include a interleukin-2 protein moiety joined to a Bcl-2 family member protein moiety.Type: GrantFiled: September 24, 2014Date of Patent: September 22, 2020Assignee: Medicenna Therapeutics Inc.Inventor: Fahar Merchant
-
Patent number: 10780128Abstract: We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may comprise a vesicle or an exosome.Type: GrantFiled: July 28, 2014Date of Patent: September 22, 2020Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)Inventor: Sai Kiang Lim
-
Patent number: 10772967Abstract: The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.Type: GrantFiled: February 7, 2020Date of Patent: September 15, 2020Inventor: Mamoun M Alhamadsheh
-
Patent number: 10774149Abstract: The invention provides fusion proteins comprising antigens of infectious disease agents and cancer cells linked to multiple-trimer forms of TNF SuperFamily (TNFSF) ligands. The TNFSFs serve as vaccine adjuvants for increasing the immune response to the antigens. In particular, a fusion polypeptide strand that self-assembles inside cells into a multiple-trimer form of CD40 ligand (CD40L, TNFSF5) is provided. Other similar fusion proteins are also disclosed. The fusion proteins can be delivered to a host as isolated proteins, as nucleic acids used directly in DNA vaccination or carried and expressed by a viral vector such as adenovirus. In addition to use as a vaccine to prevent or ameliorate disease caused by an infectious agent, compositions of the invention may be used for the treatment of ongoing infection or for cancer immunotherapy.Type: GrantFiled: August 2, 2018Date of Patent: September 15, 2020Assignee: UNIVERSITY OF MIAMIInventors: Geoffrey W. Stone, Richard S. Kornbluth
-
Patent number: 10765135Abstract: The present invention provides novel compositions and methods for producing protein-polysaccharide conjugates in aqueous solutions. Also provided are methods for limiting the Maillard reaction to the very initial stage, the formation of the Schiff base. Provided are methods to obtain a simple product of Schiff base with white color, and compositions obtained using the methods of the present invention.Type: GrantFiled: March 19, 2009Date of Patent: September 8, 2020Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: John A. Lucey, Dani Zhu, Srinivasan Damodaran
-
Patent number: 10744160Abstract: Aspects of the invention relate to a novel mesenchymal stem cell line (hb-MSC), a culture medium conditioned by the hb-MSC line, and various hb-MSC compositions. The hb-MSC composition may include a plurality of hb-MSCs, an hb-MSC conditioned medium, or a combination thereof. The hb-MSC composition may also include an appropriate carrier. Also described are methods of use for the hb-MSC cells, the conditioned medium and compositions thereof.Type: GrantFiled: November 30, 2015Date of Patent: August 18, 2020Assignee: T-Helper Cell Technologies, LLCInventors: Anatoliy Sokolov, Antonina Ivanovna Kolesnikova, Andrei Igorevich Dovgii
-
Patent number: 10738096Abstract: Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.Type: GrantFiled: July 27, 2017Date of Patent: August 11, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: K. Christopher Garcia, Darren L. Bates, Ignacio Moraga
-
Patent number: 10739262Abstract: A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.Type: GrantFiled: April 7, 2017Date of Patent: August 11, 2020Assignee: HYCOR Biomedical, LLCInventors: Mark David Van Cleve, Elaine Grace Taine, Douglas John Canfield, Stephanie TuVi Ortega, Taylor Addison Reid
-
Patent number: 10736974Abstract: Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.Type: GrantFiled: October 22, 2015Date of Patent: August 11, 2020Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray, Ying Chen, Xing Yang
-
Patent number: 10729675Abstract: A gossypol isatin Schiff base compound with antitumor activities represented by formula I: R1 and R2 are independently hydrogen, alkyl, cycloalkyl, alkoxy, nitro, halogen, unsubstituted or substituted phenyl, or unsubstituted or substituted benzyl. A method of preparing the compound of formula I is also disclosed.Type: GrantFiled: February 7, 2019Date of Patent: August 4, 2020Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Chengyuan Liang, Xingke Ju, Shunjun Ding, Lei Tian, Yuzhi Liu, Xiaolin Xie, Dezhu Zhang, Wenbo Yao, Dan Yang
-
Patent number: 10722500Abstract: A gossypol 7-N-isatin Schiff base compounds compound with antitumor activities represented by formula I: is disclosed. In formula I, R is hydrogen, alkyl, cycloalkyl, alkoxy, unsubstituted or substituted phenyl, or substituted or substituted benzyl. A method of preparing the compound of formula I is also disclosed.Type: GrantFiled: February 7, 2019Date of Patent: July 28, 2020Assignee: SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD.Inventors: Xiaolin Xie, Dezhu Zhang, Shunjun Ding, Chengyuan Liang
-
Patent number: 10685790Abstract: The present invention relates to a supercapacitor and a method for expanding the voltage range of an aqueous electrolyte supercapacitor.Type: GrantFiled: June 28, 2017Date of Patent: June 16, 2020Assignee: INNOCELL APSInventors: Steffen Thrane Vindt, Peter Brilner Lund, Eivind Skou, Shuang Ma Andersen, Steen Yde-Andersen, Jørgen Scherning Lundsgaard
-
Patent number: 10682390Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: July 14, 2016Date of Patent: June 16, 2020Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Patent number: 10682340Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: GrantFiled: December 28, 2017Date of Patent: June 16, 2020Assignees: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma Tamraz, Huey-Ching Su, WeiQi Lin, Kazuhito Yamada, Naoki Matsumoto, Sreenivasu Mudumba, Komei Okabe
-
Patent number: 10669312Abstract: The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (IL)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of NF-?B and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK signaling pathway, and suppresses the expression of a RANKL or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (TRAP), cathepsin K, or TNF receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration. Moreover, the peptide of the present invention can contribute to osteoblast differentiation by promoting the expression of osteoblast differentiation markers such as osteocalcin (OCN), osteoprotegerin (OPG), bone sialoprotein (BSP), or osteopontin (OPN).Type: GrantFiled: January 19, 2018Date of Patent: June 2, 2020Assignee: CAREGEN CO., LTD.Inventors: Yong-Ji Chung, Eun-Mi Kim, Eung-Ji Lee, Tae-Hoon Lee, A-Reum Han
-
Patent number: 10646507Abstract: Compositions and methods for improving transperitoneal oxygen uptake during peritoneal ventilation for extrapulmonary oxygenation of an organism or individual organs in preferably life-threatening case of need, such as pulmonary failure or circulatory shock, are disclosed. Such deficiencies can be addressed by transperitoneal administration of oxygen via a gas introduced into the abdominal cavity. A liquid, preferably aqueous, composition including an oxygen carrier such as hemoglobin is used, which, surprisingly, is capable of increasing the effectiveness of the diffusion of the oxygen administered by a one-time or repeated filling or continuous flushing of the abdominal cavity. An oxygen carrier, such as hemoglobin or derivatives thereof, is used for the manufacture of a composition for improvement of the diffusion of oxygen (gas) introduced into mucus layers of the peritoneum, preferably to enhance the diffusion of oxygen in transperitoneal ventilation.Type: GrantFiled: August 27, 2014Date of Patent: May 12, 2020Assignee: Sangui BioTech International, Inc.Inventors: Harald Poetzschke, Hubertus Schmelz
-
Patent number: 10632193Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.Type: GrantFiled: December 24, 2015Date of Patent: April 28, 2020Assignee: NEXIMMUNE, INC.Inventor: Bruce McCreedy
-
Patent number: 10633385Abstract: There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidinone having the structure of Formula I herein.Type: GrantFiled: March 20, 2019Date of Patent: April 28, 2020Assignee: THE SCRIPPS RESEARCH INSTITUTEInventors: Kim D. Janda, Nicholas T. Jacob, Jonathan W. Lockner
-
Patent number: 10627411Abstract: The present invention is a method for determining the identity of the epitopes recognized by T-cells. The method consists of expressing an encoded library of candidate epitope sequences in a recipient reporter cell capable of providing a detectable signal upon cytotoxic attack from a single cognate T-cell followed by contacting the reporter cells with T-cells of interest. The reporter cells with a single indicating cytotoxic attack from a T-cell are isolated and then analyzed by next-generation sequencing in order to identify the epitope sequences. Specifically disclosed is a method in which a library of candidate epitope-encoding nucleic acids are expressed in cells which feature a membrane-bound major histocompatibility complex (MHC) protein, said library produced by transfection of plasmids featuring both a nucleotide encoding the candidate epitope and a nucleotide encoding a FRET-based fluorescent protein cleaved by granzyme.Type: GrantFiled: March 25, 2015Date of Patent: April 21, 2020Assignee: British Columbia Cancer Agency BranchInventors: Robert Holt, Govinda Sharma
-
Patent number: 10626155Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15R?) or derivatives thereof; and uses thereof.Type: GrantFiled: July 19, 2016Date of Patent: April 21, 2020Assignees: Cytune Pharma, INSERM (Institut National De La Sante Et De La Recherche Medicale)Inventors: Sebastien Daniel Morisseau, Geraldine Teppaz, Yannick Laurent Joseph Jacques, Bruno Gilbert Marc Robert, Guy Luc Michel De Martynoff, David Bechard
-
Patent number: 10624965Abstract: The present invention relates to compositions and kits comprising a peptide that activate the immune response and methods of using the composition for immunotherapy and cancer treatments. The peptide comprises an active peptide sequence of VQATQSNQHTPR. In some embodiments, the peptide may be tetravalent. For example, the peptide has the structure [(VQATQSNQHTPRGGGS)2K]2K—NH2. In some embodiments, the compositions and methods are directed to the treatment of cancer and/or infections.Type: GrantFiled: December 17, 2015Date of Patent: April 21, 2020Assignee: Susavion Biosciences, Inc.Inventors: Laura L. Eggink, J. Kenneth Hoober
-
Patent number: 10618970Abstract: Methods of treating subjects having a proliferative disease, disorder, or condition, including cancer, via the administration of an IL-10 agent, including pegylated IL-10, in combination with an antibody capable of inducing anti-body-dependent cell-mediated cytotoxicity, are provided.Type: GrantFiled: February 1, 2016Date of Patent: April 14, 2020Assignee: Armo BioSciences, Inc.Inventors: John Brian Mumm, Ivan Ho Chan
-
Patent number: 10612076Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.Type: GrantFiled: April 10, 2017Date of Patent: April 7, 2020Assignees: The Children's Medical Center Corporation, The U.S.A., As Represented by the Secretary, Department of Health & Human ServicesInventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
-
Patent number: 10611790Abstract: Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, and compositions comprising such compounds that are useful for increasing the amount of NAD+ in cells. Also disclosed are methods of using the disclosed compounds and compositions for treating mitochondrial-related diseases or disorders.Type: GrantFiled: November 2, 2016Date of Patent: April 7, 2020Assignee: Mitobridge, Inc.Inventors: Arthur Kluge, Nan Ji
-
Patent number: 10576129Abstract: The present invention discloses a nerve growth factor composition and an injection powder comprising a nerve growth factor, a stabilizer, a pH buffer, and water, wherein the stabilizer is at least one of sorbitol, dextran, trehalose, raffinose and mannitol. By using a carbohydrate or sugar alcohol as a stabilizer, the present invention can avoid the potential risk resulting from the presence of viruses or other unknown components in albumin. In addition to the nerve growth factor, only the stabilizer and the pH buffer are contained, without conventional surfactant and supporting agent, increasing safety and significantly reducing incidence of the adverse reactions. The present invention not only provides a protective effect on mNGF, but also can ensure good stability of hNGF and rhNGF in the preparation, transportation and storage processes, and has better medication safety and quality control.Type: GrantFiled: April 18, 2016Date of Patent: March 3, 2020Assignees: Staidson (Beijing) Biopharmaceuticals Co., Ltd., Beijing Staidson Medical Technology Co., Ltd.Inventors: Jianping Tan, Bingzhang Wang
-
Patent number: 10548949Abstract: Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panx1 hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein.Type: GrantFiled: August 3, 2016Date of Patent: February 4, 2020Assignee: The Feinstein Institutes for Medical ResearchInventors: Haichao Wang, Wei Li, Kevin J. Tracey, Ping Wang